Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds far faster than those who end conventional diet and exercise plans.
Published data in a prominent health publication points out that while obese people frequently drop substantial amounts of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users buying these drugs must be aware of the danger of quick weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to original weight within about one and a half years.
Weighing Therapies
The analysis, which reviewed 37 of studies involving thousands of participants, contrasted the effects of the injectable medications with conventional dieting.
Researchers emphasize that people who lose weight through dieting generally have a less rapid creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Experts believe the mechanism of the jabs is key to understanding the amplified regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels several times higher than normal could lead to the body to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement leads to hunger is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the likelihood of relapse, the treatment should be considered life-long.
This view is reinforced by pharmaceutical companies, who say that the findings "emphasize the persistent character of excess weight," similar to managing conditions like hypertension.
User Experiences
Users who have come off the medication explain a intense return of appetite.
"I experienced something flipping and you become ravenous," recalled a patient.
This difficulty is exacerbated if users have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic fix and maintained weight loss relies on integrated behavioural changes.
